Fibrin clot properties and haemostatic function in men and women with type 1 diabetes

Summary

The increased risk of vascular complications in type 1 diabetes may in part be explained by changes in haemostatic function. In the present study, we investigated the fibrin clot properties in patients with type 1 diabetes in relation to sex and microvascular complications. The study included 236 patients (107 women) aged between 20–70 years and without any history of cardiovascular disease. Fibrin clot properties, assessed by determination of the permeability coefficient (Ks) and turbidimetric clotting and lysis assays, did not differ between men and women. Compared with men, women had worse glycaemic control as well as higher levels of prothrombin fragment 1+2 and peak thrombin generation in vitro, indicating increased thrombin generation both in vivo and in vitro. Subgroup analyses of patients younger than 30 years revealed less permeable fibrin clots and prolonged lysis time in females compared with age-matched men. Patients with microvascular complications had higher fibrinogen concentrations and denser and less permeable fibrin clots. Thus, we conclude that in vitro fibrin clot properties in patients with type 1 diabetes without cardiovascular disease are not different between the sexes, but associate with prevalence of microvascular complications. Tighter fibrin clot formation in younger women, as suggested by our results, may affect their future cardiovascular risk and should be investigated in a larger population.

Keywords

Fibrin clot - type 1 diabetes - microangiopathy

• References

• 1 Soedamah-Muthu SS, Fuller JH, Mulnier HE. et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U. K.: a cohort study using the general practice research database. Diabetes Care 2006; 29: 798-804.
• 2 Juutilainen A, Lehto S, Rönnemaa T. et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008; 31: 714-719.
• 3 Pencina MJ, D‘Agostino Sr RB, Larson MG. et al. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation 2009; 119: 3078-3084.
• 4 Anand SS, Islam S, Rosengren A. et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932-940.
• 5 Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-1250.
• 6 Ceriello A, Taboga C, Giacomello R. et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994; 43: 430-432.
• 7 Knöbl P, Schernthaner G, Schnack C. et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1045-1050.
• 8 Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arte-rioscler Thromb Vasc Biol 2011; 31: 494-499.
• 9 Collet JP, Park D, Lesty C. et al. Influence on fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
• 10 Fatah K, Silveira A, Tornvall P. et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
• 11 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hy-pofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 12 Rooth E, Wallen NH, Blombäck M, He S. Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke. Thromb Res 2011; 127: 51-56.
• 13 Collet JP, Mishal Z, Lesty C. et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost 1999; 82: 1482-1489.
• 14 Lütjens A, Jonkhoff-Slok TW, Sandkuijl C. et al. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 1988; 31: 825-830.
• 15 Jörneskog G, Egberg N, Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
• 16 Jörneskog G, Hansson LO, Wallen NH. et al. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 01: 1195-1201.
• 17 Blombäck B, Carlsson K, Hessel B. et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
• 18 Blombäck B, Carlsson K, Fatah K. et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
• 19 He S, Cao H, Antovic A. et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis 2005; 16: 61-67.
• 20 Antovic A, Jörneskog G, Wallen NH. Comparison of two laboratory assays for the investigation of fibrin gel porosity. Thromb Haemost 2007; 98: 1386-1388.
• 21 Carter AM, Cymbalista CM, Spector TD. et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-2789.
• 22 Hemker HC, Al Dieri R, De Smedt E. et al. Thrombin generation, a function test of the haemostatic-thrombotic system. J Thromb Haemost 2006; 96: 553-561.
• 23 Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glo-merular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
• 24 Alzahrani SH, Hess K, Price JF. et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 2012; 97: E2282-2287.
• 25 Zabczyk M, Hondo L, Krzek M. et al. High-density cholesterol and apolipopro-tein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals. Blood Coagul Fibrinolysis 2013; 24: 50-54.
• 26 Mortensen HB, Robertson KJ, Aanstoot HJ. et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes.Diabet Med 1998; 15: 752-759.
• 27 Schwab KO, Doerfer J, Marg W. et al. Characterization of 33 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. Pediatr Diabetes 2010; 11: 357-363.
• 28 Hoffman RP, Vicini P, Sivitz WI. et al. Pubertal adolescent male-female differences in insulin sensitivity and glucose effectiveness determined by the one compartment minimal model. Pediatr Res 2000; 48: 384-388.
• 29 Jensen T, Stender S, Deckert T. Abnormalities in plasmas concentrations of lipo-proteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988; 31: 142-145.
• 30 Sjolie AK, Stephenson J, Aldington S. et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997; 104: 252-260.
• 31 Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121: 1712-1719.
• 32 Brummel-Ziedins K, Vossen CY, Rosendaal FR. et al. The plasma hemostatic proteome: thrombin generation in healthy individuals. Thromb Haemost 2005; 03: 1472-1481.